Business Context and Reporting Period
Viatris Inc. filed this Form 8-K on November 16, 2020, with the report signed on November 19, 2020. The company, formerly Upjohn Inc., was formed through the consummation of a Reverse Morris Trust combination of Mylan N.V. and Pfizer’s Upjohn off-patent branded and generic established medicines business.
- Pfizer contributed the Upjohn Business to Viatris and distributed its Viatris shares pro rata to Pfizer stockholders of record on November 13, 2020.
- Immediately afterward, Viatris and Mylan completed the strategic combination.
- Pfizer stockholders received approximately 57% and former Mylan shareholders approximately 43% of Viatris’ outstanding shares, on a fully diluted, as-converted and as-exercised basis.
- Viatris paid Pfizer $12 billion in cash as partial consideration for the contribution.
Financial Metrics, Liquidity and Capital Structure
The filing does not provide a clear value for revenue, net income, operating margin, cash flow, debt balances, liquidity, or other periodic financial metrics.
The filing identifies a $12 billion cash payment to Pfizer related to the transaction but does not describe the source of funds, resulting debt, remaining cash, or pro forma liquidity.
Required financial statements for the acquired business and pro forma financial information were not included with this filing and were expected to be filed by amendment within 71 calendar days after the filing deadline.
Material Changes Versus the Prior Comparable Period
- Upjohn Inc. changed its name to Viatris Inc. effective November 16, 2020.
- Viatris became the combined company holding the Upjohn and Mylan businesses.
- Control and ownership structure changed following the Pfizer distribution and Mylan combination.
- The company adopted a new board, executive leadership team, board committees, amended governing documents, a new executive code of ethics, and the Viatris Inc. 2020 Stock Incentive Plan.
Guidance, Outlook, Risks and Unusual Items
- Viatris announced a global restructuring program intended to achieve $1 billion of synergies over the next four years, or sooner.
- The program is expected to rationalize the global manufacturing and supply network and optimize functional and commercial capabilities.
- A significant portion of the actions was expected to be phased in over the following two years.
- Expected costs include severance and other employee-related costs, asset impairments, accelerated depreciation, contract termination costs, and other closure costs.
- At the filing date, the specific restructuring parameters, total expected costs, future cash expenditures, and annual savings had not been finalized. Management expected to provide additional details by the end of 2020.
- The transaction included transition services, tax, employee matters, manufacturing and supply, intellectual property, and trademark agreements with Pfizer, creating ongoing execution and separation-related dependencies.
Leadership and Compensation Changes
- Robert J. Coury became Executive Chairman, Michael Goettler became Chief Executive Officer, Rajiv Malik became President, Sanjeev Narula became Chief Financial Officer, and Paul Campbell became Chief Accounting Officer.
- Thirteen directors were elected to the Viatris board, and eight board committees were established.
- Paul Campbell received a $600,000 transaction-based retention award. The filing also discloses compensation and severance arrangements involving Mr. Campbell and compensation of his spouse, Angela Campbell, a Viatris employee.
Most Important Facts for Investors to Verify
- Review the subsequently filed acquired-business financial statements and pro forma financial information, including revenue, earnings, debt, cash, and leverage.
- Verify the financing and liquidity impact of the $12 billion cash payment to Pfizer.
- Assess the finalized restructuring plan, including estimated charges, cash costs, timing, workforce reductions, and realized versus targeted $1 billion synergies.
- Review the detailed terms and financial obligations under the transition services, tax, manufacturing, supply, intellectual property, and trademark agreements.
- Evaluate integration risks associated with combining Mylan and Upjohn, including manufacturing-network changes, operational execution, and reliance on Pfizer transition arrangements.
- Monitor related-party and executive compensation arrangements, including the transaction-based retention award and agreements involving the Coury Firm and Campbell family members.